Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prosthesis-Related Infections | 57 | 2021 | 174 | 14.140 |
Why?
|
Defibrillators, Implantable | 52 | 2021 | 192 | 13.310 |
Why?
|
Pacemaker, Artificial | 44 | 2020 | 171 | 10.900 |
Why?
|
Endocarditis | 30 | 2022 | 105 | 7.550 |
Why?
|
Endocarditis, Bacterial | 23 | 2022 | 135 | 6.700 |
Why?
|
Bacteremia | 24 | 2022 | 401 | 6.330 |
Why?
|
Staphylococcal Infections | 24 | 2021 | 561 | 5.120 |
Why?
|
Anti-Bacterial Agents | 60 | 2025 | 2406 | 4.490 |
Why?
|
Nanoparticles | 22 | 2025 | 253 | 4.130 |
Why?
|
Chitosan | 11 | 2022 | 31 | 2.680 |
Why?
|
Staphylococcus aureus | 17 | 2025 | 466 | 2.250 |
Why?
|
Drug Carriers | 12 | 2023 | 111 | 2.170 |
Why?
|
Rhinoplasty | 3 | 2024 | 45 | 2.170 |
Why?
|
Drug Delivery Systems | 14 | 2023 | 205 | 1.950 |
Why?
|
Humans | 217 | 2025 | 126330 | 1.880 |
Why?
|
Metal Nanoparticles | 6 | 2021 | 47 | 1.860 |
Why?
|
Cross Infection | 5 | 2018 | 316 | 1.820 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 8 | 2023 | 221 | 1.810 |
Why?
|
Water Pollutants, Chemical | 3 | 2024 | 26 | 1.790 |
Why?
|
Acinetobacter | 3 | 2020 | 8 | 1.790 |
Why?
|
Polychlorinated Biphenyls | 3 | 2023 | 11 | 1.750 |
Why?
|
Hydrocarbons, Chlorinated | 3 | 2023 | 15 | 1.740 |
Why?
|
Heart Valve Prosthesis | 5 | 2022 | 303 | 1.670 |
Why?
|
Pakistan | 19 | 2025 | 90 | 1.610 |
Why?
|
Aged | 81 | 2025 | 19962 | 1.590 |
Why?
|
Bacterial Adhesion | 4 | 2020 | 101 | 1.590 |
Why?
|
Pesticides | 2 | 2023 | 25 | 1.590 |
Why?
|
Hot Temperature | 3 | 2022 | 140 | 1.580 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2017 | 149 | 1.510 |
Why?
|
Device Removal | 19 | 2018 | 217 | 1.480 |
Why?
|
Male | 122 | 2025 | 62031 | 1.480 |
Why?
|
Biofilms | 3 | 2025 | 86 | 1.430 |
Why?
|
Hydrogels | 14 | 2023 | 99 | 1.430 |
Why?
|
Soil Pollutants | 4 | 2024 | 12 | 1.430 |
Why?
|
Acinetobacter Infections | 4 | 2022 | 29 | 1.390 |
Why?
|
Anti-Infective Agents | 8 | 2025 | 261 | 1.390 |
Why?
|
Immunocompromised Host | 5 | 2019 | 293 | 1.380 |
Why?
|
Cellulose | 6 | 2024 | 26 | 1.370 |
Why?
|
Bacterial Infections | 6 | 2021 | 304 | 1.330 |
Why?
|
Antifungal Agents | 9 | 2022 | 294 | 1.310 |
Why?
|
Middle Aged | 73 | 2025 | 27031 | 1.290 |
Why?
|
Equipment Contamination | 3 | 2020 | 36 | 1.250 |
Why?
|
Air Pollutants | 2 | 2023 | 105 | 1.230 |
Why?
|
Microbial Sensitivity Tests | 17 | 2025 | 800 | 1.230 |
Why?
|
Gram-Positive Bacterial Infections | 6 | 2019 | 75 | 1.230 |
Why?
|
Histoplasmosis | 3 | 2019 | 48 | 1.220 |
Why?
|
Echocardiography, Transesophageal | 9 | 2021 | 251 | 1.180 |
Why?
|
Heart-Assist Devices | 5 | 2019 | 1028 | 1.180 |
Why?
|
Lyme Disease | 2 | 2019 | 35 | 1.170 |
Why?
|
Female | 105 | 2025 | 67333 | 1.140 |
Why?
|
Nasal Septum | 2 | 2024 | 18 | 1.130 |
Why?
|
Adult | 58 | 2025 | 29802 | 1.130 |
Why?
|
Saccharum | 3 | 2023 | 10 | 1.120 |
Why?
|
Gram-Negative Bacteria | 4 | 2019 | 70 | 1.120 |
Why?
|
Positron Emission Tomography Computed Tomography | 2 | 2017 | 79 | 1.080 |
Why?
|
Retrospective Studies | 53 | 2024 | 16517 | 1.070 |
Why?
|
Catheter-Related Infections | 2 | 2018 | 99 | 1.060 |
Why?
|
Polymers | 6 | 2022 | 109 | 1.040 |
Why?
|
Fever | 4 | 2019 | 299 | 1.030 |
Why?
|
Cleft Lip | 2 | 2023 | 128 | 1.020 |
Why?
|
Surgical Wound Infection | 4 | 2020 | 261 | 1.010 |
Why?
|
Models, Theoretical | 3 | 2022 | 370 | 1.000 |
Why?
|
Kidney Failure, Chronic | 3 | 2022 | 890 | 0.990 |
Why?
|
Environmental Monitoring | 4 | 2023 | 70 | 0.980 |
Why?
|
Nanostructures | 2 | 2022 | 52 | 0.960 |
Why?
|
Wound Healing | 9 | 2024 | 467 | 0.950 |
Why?
|
Thiazoles | 2 | 2018 | 99 | 0.950 |
Why?
|
Diarrhea | 2 | 2018 | 316 | 0.940 |
Why?
|
Drug Resistance, Multiple, Bacterial | 4 | 2025 | 133 | 0.940 |
Why?
|
Nose Deformities, Acquired | 1 | 2024 | 13 | 0.920 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 653 | 0.910 |
Why?
|
Trametes | 1 | 2024 | 1 | 0.910 |
Why?
|
Textiles | 1 | 2024 | 10 | 0.900 |
Why?
|
Hospitalization | 9 | 2021 | 1800 | 0.890 |
Why?
|
Antiviral Agents | 8 | 2021 | 769 | 0.890 |
Why?
|
Antibiotic Prophylaxis | 4 | 2018 | 116 | 0.890 |
Why?
|
Arrhythmias, Cardiac | 8 | 2020 | 463 | 0.880 |
Why?
|
Decision Support Techniques | 3 | 2015 | 297 | 0.850 |
Why?
|
Antineoplastic Agents | 5 | 2019 | 1725 | 0.850 |
Why?
|
Diagnostic Imaging | 3 | 2020 | 280 | 0.850 |
Why?
|
Pseudomonas aeruginosa | 3 | 2025 | 168 | 0.850 |
Why?
|
Gentamicins | 3 | 2023 | 94 | 0.840 |
Why?
|
Plant Extracts | 4 | 2021 | 126 | 0.840 |
Why?
|
Biological Availability | 9 | 2022 | 147 | 0.830 |
Why?
|
Aged, 80 and over | 31 | 2021 | 6645 | 0.830 |
Why?
|
Manure | 1 | 2022 | 4 | 0.800 |
Why?
|
Biofuels | 1 | 2022 | 7 | 0.800 |
Why?
|
Mucormycosis | 3 | 2017 | 28 | 0.790 |
Why?
|
Aspergillus fumigatus | 2 | 2017 | 42 | 0.780 |
Why?
|
Environmental Pollutants | 1 | 2023 | 71 | 0.780 |
Why?
|
Hydrodynamics | 1 | 2022 | 26 | 0.780 |
Why?
|
Risk Factors | 29 | 2021 | 10375 | 0.760 |
Why?
|
Administration, Oral | 10 | 2021 | 700 | 0.740 |
Why?
|
Burns | 4 | 2024 | 79 | 0.730 |
Why?
|
Young Adult | 27 | 2025 | 9174 | 0.730 |
Why?
|
Psoas Abscess | 1 | 2021 | 3 | 0.720 |
Why?
|
Silver | 4 | 2021 | 24 | 0.720 |
Why?
|
Actinobacteria | 1 | 2021 | 13 | 0.720 |
Why?
|
Wound Infection | 2 | 2021 | 54 | 0.720 |
Why?
|
Treatment Outcome | 30 | 2024 | 12380 | 0.710 |
Why?
|
Ionic Liquids | 1 | 2020 | 3 | 0.710 |
Why?
|
Polysaccharides | 2 | 2024 | 141 | 0.710 |
Why?
|
Algorithms | 5 | 2024 | 1647 | 0.700 |
Why?
|
Risk Assessment | 16 | 2024 | 3461 | 0.700 |
Why?
|
Bacillus | 1 | 2020 | 35 | 0.700 |
Why?
|
Animals | 44 | 2023 | 34533 | 0.700 |
Why?
|
Data Accuracy | 1 | 2020 | 26 | 0.690 |
Why?
|
Polymyxins | 1 | 2020 | 15 | 0.690 |
Why?
|
Transplant Recipients | 2 | 2019 | 220 | 0.690 |
Why?
|
Frailty | 1 | 2022 | 110 | 0.680 |
Why?
|
Spinal Cord Stimulation | 1 | 2020 | 10 | 0.680 |
Why?
|
Renal Dialysis | 3 | 2022 | 862 | 0.670 |
Why?
|
Xylenes | 1 | 2020 | 13 | 0.670 |
Why?
|
Transdermal Patch | 1 | 2020 | 8 | 0.670 |
Why?
|
beta-Lactam Resistance | 2 | 2017 | 47 | 0.670 |
Why?
|
Sulfhydryl Compounds | 5 | 2020 | 60 | 0.670 |
Why?
|
Cellulitis | 2 | 2017 | 63 | 0.670 |
Why?
|
Radiopharmaceuticals | 2 | 2017 | 172 | 0.660 |
Why?
|
Coated Materials, Biocompatible | 1 | 2020 | 38 | 0.660 |
Why?
|
Gram-Positive Bacteria | 2 | 2019 | 47 | 0.650 |
Why?
|
Community-Acquired Infections | 3 | 2018 | 240 | 0.640 |
Why?
|
Pain | 3 | 2020 | 453 | 0.640 |
Why?
|
Musculoskeletal Pain | 1 | 2019 | 14 | 0.640 |
Why?
|
Anaplasmosis | 1 | 2019 | 2 | 0.640 |
Why?
|
Clostridium Infections | 2 | 2014 | 246 | 0.640 |
Why?
|
Tacrolimus | 1 | 2020 | 99 | 0.640 |
Why?
|
Myalgia | 1 | 2019 | 11 | 0.640 |
Why?
|
Publishing | 1 | 2020 | 113 | 0.630 |
Why?
|
Metformin | 1 | 2021 | 153 | 0.620 |
Why?
|
Multimodal Imaging | 2 | 2020 | 116 | 0.620 |
Why?
|
Cryptococcosis | 1 | 2019 | 42 | 0.620 |
Why?
|
Biological Products | 1 | 2021 | 128 | 0.620 |
Why?
|
Nanocapsules | 1 | 2018 | 8 | 0.610 |
Why?
|
Aircraft | 2 | 2011 | 20 | 0.600 |
Why?
|
Minnesota | 11 | 2021 | 144 | 0.600 |
Why?
|
Adenoviridae Infections | 1 | 2018 | 71 | 0.590 |
Why?
|
Invasive Fungal Infections | 1 | 2018 | 13 | 0.590 |
Why?
|
Metals, Heavy | 3 | 2024 | 23 | 0.590 |
Why?
|
Enteritis | 1 | 2018 | 54 | 0.590 |
Why?
|
Larynx | 1 | 2019 | 72 | 0.580 |
Why?
|
Coronavirus Infections | 2 | 2020 | 367 | 0.580 |
Why?
|
Taxoids | 1 | 2018 | 68 | 0.580 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 381 | 0.580 |
Why?
|
Cost of Illness | 1 | 2020 | 255 | 0.580 |
Why?
|
Diagnosis, Differential | 10 | 2018 | 1909 | 0.580 |
Why?
|
Postoperative Complications | 6 | 2019 | 3078 | 0.580 |
Why?
|
Dust | 1 | 2017 | 19 | 0.570 |
Why?
|
Hyaluronic Acid | 5 | 2023 | 103 | 0.570 |
Why?
|
Borrelia burgdorferi | 1 | 2018 | 20 | 0.570 |
Why?
|
Cranial Nerve Diseases | 1 | 2018 | 26 | 0.570 |
Why?
|
Heart Failure | 4 | 2022 | 2309 | 0.560 |
Why?
|
Bartonella Infections | 1 | 2017 | 7 | 0.560 |
Why?
|
Medicare | 3 | 2020 | 433 | 0.560 |
Why?
|
Pulmonary Aspergillosis | 1 | 2017 | 11 | 0.560 |
Why?
|
Bartonella henselae | 1 | 2017 | 19 | 0.560 |
Why?
|
Folic Acid | 2 | 2023 | 295 | 0.560 |
Why?
|
Shock, Septic | 1 | 2019 | 148 | 0.560 |
Why?
|
Costal Cartilage | 1 | 2017 | 4 | 0.560 |
Why?
|
Travel | 2 | 2011 | 115 | 0.560 |
Why?
|
Triazoles | 2 | 2017 | 140 | 0.560 |
Why?
|
Mitral Valve Insufficiency | 1 | 2019 | 164 | 0.560 |
Why?
|
Cardiologists | 1 | 2017 | 20 | 0.560 |
Why?
|
Mediastinum | 1 | 2017 | 43 | 0.560 |
Why?
|
Firmicutes | 1 | 2017 | 21 | 0.550 |
Why?
|
Herpes Zoster | 1 | 2017 | 25 | 0.550 |
Why?
|
Amphotericin B | 4 | 2019 | 91 | 0.540 |
Why?
|
Nephritis, Interstitial | 1 | 2017 | 38 | 0.540 |
Why?
|
Fluoroquinolones | 1 | 2017 | 86 | 0.540 |
Why?
|
Brain Abscess | 1 | 2017 | 52 | 0.540 |
Why?
|
Drug Therapy, Combination | 4 | 2018 | 1168 | 0.540 |
Why?
|
Bacteria | 4 | 2022 | 486 | 0.540 |
Why?
|
ST Elevation Myocardial Infarction | 1 | 2019 | 116 | 0.540 |
Why?
|
Hypokalemia | 1 | 2017 | 41 | 0.530 |
Why?
|
Temporal Lobe | 1 | 2017 | 113 | 0.530 |
Why?
|
Hypromellose Derivatives | 4 | 2021 | 4 | 0.530 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2016 | 1 | 0.530 |
Why?
|
Incidence | 13 | 2021 | 3170 | 0.530 |
Why?
|
Fluorescein Angiography | 1 | 2017 | 143 | 0.530 |
Why?
|
Sepsis | 1 | 2021 | 494 | 0.530 |
Why?
|
Lip | 1 | 2016 | 14 | 0.520 |
Why?
|
Eye Infections, Bacterial | 1 | 2017 | 92 | 0.520 |
Why?
|
Abdominal Pain | 3 | 2015 | 307 | 0.520 |
Why?
|
Sclerotherapy | 1 | 2016 | 40 | 0.520 |
Why?
|
Cardiovascular Infections | 3 | 2017 | 7 | 0.520 |
Why?
|
Streptococcal Infections | 6 | 2021 | 240 | 0.510 |
Why?
|
Cardiac Resynchronization Therapy Devices | 2 | 2017 | 13 | 0.510 |
Why?
|
Zinc Oxide | 3 | 2020 | 10 | 0.510 |
Why?
|
Coinfection | 2 | 2019 | 172 | 0.510 |
Why?
|
Finite Element Analysis | 4 | 2022 | 32 | 0.500 |
Why?
|
Adenoviridae | 1 | 2018 | 602 | 0.500 |
Why?
|
Arthroplasty | 1 | 2015 | 17 | 0.490 |
Why?
|
Surgical Flaps | 2 | 2021 | 205 | 0.490 |
Why?
|
Patient Satisfaction | 4 | 2024 | 477 | 0.490 |
Why?
|
Vision Disorders | 1 | 2017 | 211 | 0.480 |
Why?
|
Antiprotozoal Agents | 4 | 2020 | 42 | 0.480 |
Why?
|
Comorbidity | 10 | 2018 | 1542 | 0.480 |
Why?
|
Blood Culture | 3 | 2021 | 30 | 0.480 |
Why?
|
beta-Lactamases | 1 | 2017 | 199 | 0.480 |
Why?
|
Virus Diseases | 1 | 2018 | 281 | 0.480 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2015 | 44 | 0.480 |
Why?
|
Safety | 2 | 2018 | 222 | 0.480 |
Why?
|
Health Expenditures | 1 | 2016 | 106 | 0.480 |
Why?
|
Vascular Malformations | 1 | 2016 | 92 | 0.480 |
Why?
|
Golgi Apparatus | 1 | 2015 | 91 | 0.470 |
Why?
|
Rats | 9 | 2021 | 3763 | 0.470 |
Why?
|
Particle Size | 9 | 2022 | 133 | 0.470 |
Why?
|
Adolescent | 21 | 2025 | 19548 | 0.470 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 260 | 0.460 |
Why?
|
Bandages | 4 | 2024 | 59 | 0.460 |
Why?
|
Cytokines | 1 | 2020 | 1306 | 0.460 |
Why?
|
Trichinella | 1 | 2014 | 2 | 0.450 |
Why?
|
Population Surveillance | 5 | 2018 | 396 | 0.450 |
Why?
|
Trichinellosis | 1 | 2014 | 14 | 0.450 |
Why?
|
Propionibacterium | 2 | 2016 | 4 | 0.450 |
Why?
|
Albendazole | 1 | 2014 | 29 | 0.440 |
Why?
|
Clostridium | 1 | 2014 | 17 | 0.440 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2015 | 255 | 0.440 |
Why?
|
Uterine Myomectomy | 1 | 2014 | 10 | 0.440 |
Why?
|
Embolization, Therapeutic | 1 | 2016 | 219 | 0.440 |
Why?
|
Drug Liberation | 10 | 2023 | 22 | 0.440 |
Why?
|
Prostheses and Implants | 3 | 2020 | 151 | 0.440 |
Why?
|
Stroke | 1 | 2022 | 995 | 0.440 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2015 | 232 | 0.440 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2013 | 4 | 0.430 |
Why?
|
Diabetes Mellitus | 4 | 2023 | 885 | 0.430 |
Why?
|
Albuminuria | 1 | 2014 | 103 | 0.430 |
Why?
|
Diabetic Angiopathies | 1 | 2014 | 67 | 0.430 |
Why?
|
Rabbits | 5 | 2022 | 719 | 0.430 |
Why?
|
Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2017 | 39 | 0.420 |
Why?
|
Strongyloides stercoralis | 1 | 2013 | 23 | 0.420 |
Why?
|
Haemophilus parainfluenzae | 1 | 2013 | 11 | 0.420 |
Why?
|
Strongyloidiasis | 1 | 2013 | 43 | 0.420 |
Why?
|
Kidney Transplantation | 1 | 2019 | 658 | 0.420 |
Why?
|
Bacterial Proteins | 2 | 2023 | 901 | 0.420 |
Why?
|
Leiomyoma | 1 | 2014 | 81 | 0.420 |
Why?
|
Drug Resistance, Bacterial | 5 | 2025 | 361 | 0.410 |
Why?
|
Follow-Up Studies | 14 | 2019 | 5204 | 0.410 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2020 | 119 | 0.410 |
Why?
|
Leishmaniasis | 3 | 2017 | 38 | 0.410 |
Why?
|
Embolism | 1 | 2013 | 46 | 0.410 |
Why?
|
Carrageenan | 2 | 2023 | 6 | 0.410 |
Why?
|
Alternative Splicing | 1 | 2015 | 357 | 0.410 |
Why?
|
Haemophilus Infections | 1 | 2013 | 91 | 0.400 |
Why?
|
Uterine Neoplasms | 1 | 2014 | 106 | 0.400 |
Why?
|
Typhoid Fever | 2 | 2024 | 21 | 0.400 |
Why?
|
Osteomyelitis | 1 | 2015 | 205 | 0.400 |
Why?
|
Rivers | 2 | 2023 | 11 | 0.400 |
Why?
|
Soil | 5 | 2024 | 63 | 0.400 |
Why?
|
Delayed-Action Preparations | 9 | 2022 | 117 | 0.400 |
Why?
|
Pancytopenia | 1 | 2012 | 41 | 0.390 |
Why?
|
Biocompatible Materials | 4 | 2023 | 122 | 0.390 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2019 | 618 | 0.390 |
Why?
|
Hypertension | 2 | 2020 | 1296 | 0.390 |
Why?
|
Cattle | 3 | 2022 | 567 | 0.390 |
Why?
|
Surgical Mesh | 3 | 2018 | 61 | 0.390 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 858 | 0.380 |
Why?
|
Abscess | 4 | 2018 | 139 | 0.380 |
Why?
|
Survival Rate | 9 | 2014 | 2070 | 0.380 |
Why?
|
Cellulase | 2 | 2022 | 5 | 0.380 |
Why?
|
Herpesvirus 2, Human | 1 | 2011 | 14 | 0.380 |
Why?
|
Herpes Genitalis | 1 | 2011 | 11 | 0.380 |
Why?
|
Curcumin | 2 | 2022 | 39 | 0.380 |
Why?
|
Nanomedicine | 4 | 2019 | 19 | 0.370 |
Why?
|
Hepatitis, Viral, Human | 1 | 2011 | 44 | 0.370 |
Why?
|
Escherichia coli Infections | 1 | 2013 | 183 | 0.370 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 740 | 0.360 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2011 | 42 | 0.360 |
Why?
|
RNA, Ribosomal, 16S | 3 | 2021 | 363 | 0.360 |
Why?
|
Polymerase Chain Reaction | 3 | 2021 | 1597 | 0.360 |
Why?
|
Cardiovascular Diseases | 3 | 2013 | 1969 | 0.350 |
Why?
|
Ambulatory Surgical Procedures | 2 | 2016 | 55 | 0.350 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2014 | 458 | 0.340 |
Why?
|
Miniaturization | 3 | 2020 | 27 | 0.340 |
Why?
|
Prospective Studies | 11 | 2020 | 6175 | 0.340 |
Why?
|
Disease Management | 3 | 2020 | 529 | 0.340 |
Why?
|
Brain Diseases | 1 | 2013 | 301 | 0.340 |
Why?
|
Ultrasonography | 1 | 2015 | 943 | 0.330 |
Why?
|
Curcuma | 2 | 2020 | 3 | 0.330 |
Why?
|
Cross-Sectional Studies | 7 | 2025 | 3457 | 0.330 |
Why?
|
Nose | 2 | 2023 | 95 | 0.330 |
Why?
|
Breast Neoplasms | 2 | 2020 | 2542 | 0.330 |
Why?
|
Glucans | 4 | 2022 | 15 | 0.330 |
Why?
|
Time Factors | 11 | 2019 | 6334 | 0.330 |
Why?
|
Critical Care | 2 | 2014 | 661 | 0.330 |
Why?
|
Viridans Streptococci | 3 | 2015 | 8 | 0.330 |
Why?
|
United States | 13 | 2020 | 10990 | 0.320 |
Why?
|
Reproducibility of Results | 4 | 2022 | 2900 | 0.320 |
Why?
|
Disease Transmission, Infectious | 3 | 2021 | 84 | 0.320 |
Why?
|
Ceftriaxone | 3 | 2018 | 67 | 0.320 |
Why?
|
Vancomycin | 4 | 2022 | 220 | 0.310 |
Why?
|
Carbapenems | 3 | 2022 | 38 | 0.310 |
Why?
|
Length of Stay | 6 | 2024 | 1325 | 0.310 |
Why?
|
Rejuvenation | 2 | 2019 | 12 | 0.310 |
Why?
|
Solubility | 4 | 2022 | 141 | 0.300 |
Why?
|
Pandemics | 3 | 2021 | 1129 | 0.300 |
Why?
|
Cardiac Surgical Procedures | 1 | 2017 | 1130 | 0.300 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 141 | 0.300 |
Why?
|
Leishmania | 3 | 2017 | 33 | 0.300 |
Why?
|
Leishmaniasis, Visceral | 2 | 2019 | 20 | 0.300 |
Why?
|
Prosthesis Implantation | 3 | 2016 | 142 | 0.290 |
Why?
|
Electrocardiography, Ambulatory | 2 | 2019 | 61 | 0.290 |
Why?
|
Skin | 3 | 2020 | 527 | 0.290 |
Why?
|
Surgical Procedures, Operative | 2 | 2020 | 183 | 0.280 |
Why?
|
Infection Control | 2 | 2020 | 146 | 0.280 |
Why?
|
Cell Differentiation | 1 | 2015 | 1931 | 0.280 |
Why?
|
Prevalence | 8 | 2025 | 2484 | 0.280 |
Why?
|
Age Distribution | 3 | 2016 | 422 | 0.280 |
Why?
|
Tuberculosis | 3 | 2023 | 531 | 0.280 |
Why?
|
Prognosis | 7 | 2020 | 4742 | 0.280 |
Why?
|
Tomography, X-Ray Computed | 5 | 2019 | 2106 | 0.280 |
Why?
|
Triticum | 2 | 2024 | 36 | 0.280 |
Why?
|
Alginates | 3 | 2023 | 22 | 0.270 |
Why?
|
Leprosy, Lepromatous | 1 | 2007 | 2 | 0.270 |
Why?
|
Water | 3 | 2024 | 190 | 0.270 |
Why?
|
Polygalacturonase | 2 | 2024 | 2 | 0.270 |
Why?
|
Esthetics | 2 | 2024 | 37 | 0.270 |
Why?
|
Salmonella typhi | 2 | 2024 | 18 | 0.270 |
Why?
|
Tensile Strength | 3 | 2024 | 44 | 0.270 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 649 | 0.270 |
Why?
|
Sheep | 2 | 2022 | 220 | 0.260 |
Why?
|
Anti-Inflammatory Agents | 3 | 2022 | 296 | 0.260 |
Why?
|
Green Chemistry Technology | 3 | 2021 | 3 | 0.260 |
Why?
|
Cohort Studies | 12 | 2021 | 4874 | 0.260 |
Why?
|
Polyvinyl Alcohol | 3 | 2023 | 12 | 0.250 |
Why?
|
Thermal Conductivity | 2 | 2022 | 2 | 0.250 |
Why?
|
Nitro Compounds | 2 | 2018 | 18 | 0.250 |
Why?
|
CRISPR-Cas Systems | 3 | 2022 | 259 | 0.250 |
Why?
|
Otitis Media, Suppurative | 1 | 2025 | 5 | 0.250 |
Why?
|
Odds Ratio | 3 | 2014 | 1266 | 0.240 |
Why?
|
Coccidioides | 1 | 2005 | 2 | 0.240 |
Why?
|
Infant, Newborn | 8 | 2017 | 8308 | 0.240 |
Why?
|
Adipose Tissue | 2 | 2019 | 470 | 0.240 |
Why?
|
Coccidioidomycosis | 1 | 2005 | 12 | 0.240 |
Why?
|
X-Ray Diffraction | 6 | 2021 | 100 | 0.240 |
Why?
|
Male Urogenital Diseases | 1 | 2005 | 14 | 0.240 |
Why?
|
Prosthesis Failure | 2 | 2017 | 157 | 0.240 |
Why?
|
Child | 11 | 2025 | 24766 | 0.240 |
Why?
|
Echocardiography | 4 | 2021 | 1075 | 0.240 |
Why?
|
Endo-1,4-beta Xylanases | 2 | 2024 | 2 | 0.240 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 730 | 0.230 |
Why?
|
Peripheral Vascular Diseases | 1 | 2005 | 84 | 0.230 |
Why?
|
Sewage | 1 | 2024 | 9 | 0.230 |
Why?
|
Multivariate Analysis | 4 | 2014 | 1436 | 0.230 |
Why?
|
Lignin | 2 | 2024 | 14 | 0.230 |
Why?
|
Cell Survival | 4 | 2021 | 835 | 0.230 |
Why?
|
Injections | 3 | 2023 | 158 | 0.230 |
Why?
|
Cobalt Radioisotopes | 1 | 2024 | 2 | 0.230 |
Why?
|
Thermoluminescent Dosimetry | 1 | 2024 | 11 | 0.230 |
Why?
|
Waste Disposal, Fluid | 1 | 2024 | 7 | 0.230 |
Why?
|
Fermentation | 2 | 2023 | 70 | 0.230 |
Why?
|
Nontuberculous Mycobacteria | 1 | 2004 | 25 | 0.230 |
Why?
|
Membranes, Artificial | 2 | 2021 | 29 | 0.230 |
Why?
|
Pneumonia | 3 | 2021 | 325 | 0.230 |
Why?
|
Heparin | 2 | 2022 | 218 | 0.220 |
Why?
|
Abdominal Abscess | 1 | 2004 | 25 | 0.220 |
Why?
|
Injections, Intra-Articular | 1 | 2004 | 26 | 0.220 |
Why?
|
Pseudomonas Infections | 1 | 2025 | 117 | 0.220 |
Why?
|
Skin Transplantation | 1 | 2024 | 60 | 0.220 |
Why?
|
Parents | 1 | 2011 | 1028 | 0.220 |
Why?
|
Zea mays | 1 | 2024 | 43 | 0.220 |
Why?
|
Aspergillosis | 1 | 2004 | 44 | 0.220 |
Why?
|
Triamcinolone Acetonide | 1 | 2004 | 36 | 0.220 |
Why?
|
Hernia, Inguinal | 1 | 2004 | 42 | 0.220 |
Why?
|
Polyethylene Glycols | 3 | 2022 | 244 | 0.220 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2004 | 46 | 0.220 |
Why?
|
Tertiary Care Centers | 2 | 2022 | 245 | 0.220 |
Why?
|
Shoulder Joint | 1 | 2004 | 29 | 0.220 |
Why?
|
Transplantation, Autologous | 1 | 2024 | 275 | 0.220 |
Why?
|
Electronics | 2 | 2020 | 44 | 0.220 |
Why?
|
Radiotherapy Dosage | 1 | 2024 | 188 | 0.220 |
Why?
|
Hydrogen-Ion Concentration | 5 | 2022 | 454 | 0.210 |
Why?
|
Peptones | 1 | 2023 | 1 | 0.210 |
Why?
|
Fluconazole | 2 | 2019 | 48 | 0.210 |
Why?
|
Meningoencephalitis | 1 | 2003 | 18 | 0.210 |
Why?
|
Soil Pollutants, Radioactive | 1 | 2023 | 2 | 0.210 |
Why?
|
Equipment Design | 3 | 2020 | 595 | 0.210 |
Why?
|
Bone Regeneration | 1 | 2023 | 23 | 0.210 |
Why?
|
Radiation Monitoring | 1 | 2023 | 14 | 0.210 |
Why?
|
Phantoms, Imaging | 1 | 2024 | 136 | 0.210 |
Why?
|
Radium | 1 | 2023 | 9 | 0.210 |
Why?
|
Plastics | 1 | 2023 | 14 | 0.210 |
Why?
|
Arthritis, Infectious | 1 | 2004 | 59 | 0.210 |
Why?
|
Materials Testing | 2 | 2020 | 74 | 0.210 |
Why?
|
Pyoderma | 1 | 2023 | 2 | 0.210 |
Why?
|
Esthetics, Dental | 1 | 2023 | 15 | 0.210 |
Why?
|
Guideline Adherence | 2 | 2017 | 379 | 0.210 |
Why?
|
Microspheres | 2 | 2021 | 72 | 0.210 |
Why?
|
Gases | 1 | 2023 | 17 | 0.210 |
Why?
|
Methacrylates | 2 | 2020 | 19 | 0.210 |
Why?
|
Environmental Pollution | 1 | 2023 | 14 | 0.210 |
Why?
|
Hospital Mortality | 6 | 2017 | 1034 | 0.210 |
Why?
|
Cartilage | 1 | 2023 | 48 | 0.210 |
Why?
|
Pharmacies | 1 | 2023 | 14 | 0.210 |
Why?
|
Clove Oil | 1 | 2022 | 1 | 0.210 |
Why?
|
Crop Production | 1 | 2022 | 1 | 0.200 |
Why?
|
Psidium | 1 | 2022 | 1 | 0.200 |
Why?
|
Pharmacy | 1 | 2023 | 15 | 0.200 |
Why?
|
Synovial Fluid | 1 | 2022 | 16 | 0.200 |
Why?
|
Olive Oil | 1 | 2022 | 23 | 0.200 |
Why?
|
Ciprofloxacin | 2 | 2023 | 61 | 0.200 |
Why?
|
Ampicillin | 2 | 2024 | 56 | 0.200 |
Why?
|
Bacillaceae | 1 | 2022 | 1 | 0.200 |
Why?
|
Cellulases | 1 | 2022 | 2 | 0.200 |
Why?
|
Ecosystem | 1 | 2023 | 79 | 0.200 |
Why?
|
Anaerobiosis | 1 | 2022 | 14 | 0.200 |
Why?
|
Methane | 1 | 2022 | 15 | 0.200 |
Why?
|
Silymarin | 1 | 2022 | 1 | 0.200 |
Why?
|
Rumen | 1 | 2022 | 14 | 0.200 |
Why?
|
Diabetic Foot | 1 | 2025 | 161 | 0.200 |
Why?
|
Burn Units | 1 | 2022 | 6 | 0.200 |
Why?
|
Intensive Care Units, Neonatal | 2 | 2017 | 318 | 0.200 |
Why?
|
Hand Strength | 1 | 2022 | 44 | 0.200 |
Why?
|
Neoplasms | 4 | 2024 | 2807 | 0.200 |
Why?
|
American Heart Association | 3 | 2015 | 323 | 0.200 |
Why?
|
Bioreactors | 1 | 2022 | 40 | 0.200 |
Why?
|
Hexachlorobenzene | 1 | 2022 | 2 | 0.200 |
Why?
|
Motion | 1 | 2022 | 44 | 0.200 |
Why?
|
Metal-Organic Frameworks | 1 | 2022 | 3 | 0.200 |
Why?
|
Diffusion | 1 | 2022 | 58 | 0.200 |
Why?
|
Energy Transfer | 1 | 2022 | 17 | 0.200 |
Why?
|
Polyethylenes | 1 | 2022 | 9 | 0.200 |
Why?
|
DDT | 1 | 2022 | 5 | 0.200 |
Why?
|
Dichlorodiphenyl Dichloroethylene | 1 | 2022 | 12 | 0.200 |
Why?
|
Biosensing Techniques | 1 | 2022 | 55 | 0.200 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2023 | 71 | 0.190 |
Why?
|
Logistic Models | 3 | 2014 | 1812 | 0.190 |
Why?
|
Inpatients | 2 | 2017 | 505 | 0.190 |
Why?
|
Azithromycin | 2 | 2021 | 44 | 0.190 |
Why?
|
Spectroscopy, Fourier Transform Infrared | 4 | 2024 | 34 | 0.190 |
Why?
|
Diabetes Complications | 2 | 2021 | 203 | 0.190 |
Why?
|
Mupirocin | 1 | 2022 | 20 | 0.190 |
Why?
|
Copper | 2 | 2022 | 65 | 0.190 |
Why?
|
Physical Phenomena | 1 | 2021 | 2 | 0.190 |
Why?
|
Confidence Intervals | 2 | 2013 | 283 | 0.190 |
Why?
|
Antitubercular Agents | 2 | 2023 | 254 | 0.190 |
Why?
|
HeLa Cells | 3 | 2023 | 796 | 0.190 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 305 | 0.180 |
Why?
|
West Nile Fever | 1 | 2003 | 139 | 0.180 |
Why?
|
Sweet Syndrome | 1 | 2021 | 10 | 0.180 |
Why?
|
Heart Valves | 2 | 2019 | 52 | 0.180 |
Why?
|
Phosphorous Acids | 1 | 2021 | 1 | 0.180 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 3449 | 0.180 |
Why?
|
Povidone | 1 | 2021 | 6 | 0.180 |
Why?
|
Practice Guidelines as Topic | 4 | 2015 | 1274 | 0.180 |
Why?
|
Mannose | 2 | 2018 | 25 | 0.180 |
Why?
|
Myoclonus | 1 | 2021 | 32 | 0.180 |
Why?
|
Acinetobacter baumannii | 1 | 2022 | 39 | 0.180 |
Why?
|
Liposomes | 2 | 2021 | 190 | 0.180 |
Why?
|
Graphite | 1 | 2021 | 10 | 0.180 |
Why?
|
Cardiac Catheterization | 1 | 2005 | 635 | 0.180 |
Why?
|
Polygonaceae | 1 | 2021 | 1 | 0.180 |
Why?
|
Piroxicam | 1 | 2021 | 3 | 0.180 |
Why?
|
Staphylococcus | 1 | 2021 | 68 | 0.180 |
Why?
|
Child Nutrition Disorders | 1 | 2022 | 76 | 0.180 |
Why?
|
Biological Dressings | 1 | 2020 | 5 | 0.180 |
Why?
|
Xylosidases | 1 | 2020 | 1 | 0.180 |
Why?
|
Velopharyngeal Insufficiency | 1 | 2021 | 18 | 0.180 |
Why?
|
Rifampin | 2 | 2023 | 130 | 0.180 |
Why?
|
Lasers, Excimer | 1 | 2021 | 99 | 0.180 |
Why?
|
Sodium Hydroxide | 1 | 2020 | 8 | 0.180 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 17 | 0.180 |
Why?
|
Spirochaetales | 1 | 2020 | 6 | 0.180 |
Why?
|
Chloroquine | 1 | 2021 | 31 | 0.180 |
Why?
|
Onychomycosis | 1 | 2021 | 8 | 0.180 |
Why?
|
Alkalies | 1 | 2020 | 25 | 0.180 |
Why?
|
Quaternary Ammonium Compounds | 1 | 2020 | 31 | 0.180 |
Why?
|
Candida | 2 | 2021 | 75 | 0.180 |
Why?
|
Treponema pallidum | 1 | 2020 | 50 | 0.180 |
Why?
|
Selenium | 1 | 2020 | 16 | 0.180 |
Why?
|
Acellular Dermis | 1 | 2020 | 6 | 0.170 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 80 | 0.170 |
Why?
|
Refractive Surgical Procedures | 1 | 2021 | 77 | 0.170 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2020 | 21 | 0.170 |
Why?
|
Wettability | 1 | 2020 | 2 | 0.170 |
Why?
|
Breast Implants | 1 | 2020 | 29 | 0.170 |
Why?
|
Leishmania tropica | 1 | 2020 | 2 | 0.170 |
Why?
|
Physicians' Offices | 1 | 2020 | 10 | 0.170 |
Why?
|
Membranes | 1 | 2020 | 24 | 0.170 |
Why?
|
Surgery Department, Hospital | 1 | 2020 | 20 | 0.170 |
Why?
|
Voriconazole | 2 | 2014 | 34 | 0.170 |
Why?
|
Sensitivity and Specificity | 4 | 2020 | 2068 | 0.170 |
Why?
|
Ketoprofen | 1 | 2020 | 1 | 0.170 |
Why?
|
Spine | 1 | 2021 | 140 | 0.170 |
Why?
|
Nanotubes | 1 | 2020 | 14 | 0.170 |
Why?
|
Diffusion Chambers, Culture | 1 | 2020 | 7 | 0.170 |
Why?
|
Teratogens | 1 | 2020 | 87 | 0.170 |
Why?
|
Facial Recognition | 1 | 2020 | 5 | 0.170 |
Why?
|
Reactive Oxygen Species | 2 | 2020 | 499 | 0.170 |
Why?
|
Operative Time | 2 | 2019 | 167 | 0.170 |
Why?
|
Encephalitis | 1 | 2021 | 111 | 0.170 |
Why?
|
Naproxen | 1 | 2020 | 21 | 0.170 |
Why?
|
Microinjections | 1 | 2020 | 51 | 0.170 |
Why?
|
Colony Count, Microbial | 1 | 2020 | 85 | 0.170 |
Why?
|
Syphilis | 1 | 2020 | 97 | 0.170 |
Why?
|
Enterococcus faecalis | 2 | 2018 | 44 | 0.170 |
Why?
|
Betacoronavirus | 2 | 2020 | 294 | 0.170 |
Why?
|
Ferric Compounds | 1 | 2020 | 39 | 0.160 |
Why?
|
Macrophages | 3 | 2020 | 642 | 0.160 |
Why?
|
Facial Expression | 1 | 2020 | 26 | 0.160 |
Why?
|
Light | 1 | 2020 | 177 | 0.160 |
Why?
|
Disulfides | 1 | 2020 | 80 | 0.160 |
Why?
|
Splenic Infarction | 1 | 2019 | 4 | 0.160 |
Why?
|
Sex Distribution | 2 | 2013 | 309 | 0.160 |
Why?
|
Carnobacteriaceae | 1 | 2019 | 2 | 0.160 |
Why?
|
Needles | 1 | 2020 | 52 | 0.160 |
Why?
|
Mammaplasty | 1 | 2020 | 53 | 0.160 |
Why?
|
Pregnancy Outcome | 2 | 2014 | 599 | 0.160 |
Why?
|
Mice | 10 | 2023 | 17881 | 0.160 |
Why?
|
Duloxetine Hydrochloride | 1 | 2019 | 10 | 0.160 |
Why?
|
Disease Vectors | 1 | 2019 | 24 | 0.160 |
Why?
|
Mice, Inbred BALB C | 5 | 2020 | 1006 | 0.160 |
Why?
|
Biopolymers | 1 | 2019 | 21 | 0.160 |
Why?
|
Enterococcus | 1 | 2019 | 26 | 0.160 |
Why?
|
Emulsifying Agents | 1 | 2019 | 3 | 0.160 |
Why?
|
Chlorpromazine | 1 | 2019 | 13 | 0.160 |
Why?
|
Rats, Wistar | 1 | 2020 | 382 | 0.160 |
Why?
|
Transducers | 1 | 2019 | 25 | 0.160 |
Why?
|
Itraconazole | 1 | 2019 | 25 | 0.160 |
Why?
|
Flucytosine | 1 | 2019 | 17 | 0.160 |
Why?
|
Histoplasma | 1 | 2019 | 31 | 0.160 |
Why?
|
Cryptococcus neoformans | 1 | 2019 | 21 | 0.160 |
Why?
|
Cleft Palate | 1 | 2021 | 146 | 0.160 |
Why?
|
Paromomycin | 1 | 2019 | 4 | 0.160 |
Why?
|
Wireless Technology | 1 | 2019 | 13 | 0.160 |
Why?
|
Immunocompetence | 1 | 2019 | 34 | 0.160 |
Why?
|
Domperidone | 1 | 2019 | 7 | 0.160 |
Why?
|
Sonication | 1 | 2018 | 8 | 0.160 |
Why?
|
Cicatrix, Hypertrophic | 1 | 2019 | 6 | 0.150 |
Why?
|
Heart Conduction System | 1 | 2020 | 148 | 0.150 |
Why?
|
Health Resources | 1 | 2020 | 120 | 0.150 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 26 | 0.150 |
Why?
|
Intra-Aortic Balloon Pumping | 1 | 2019 | 42 | 0.150 |
Why?
|
Pelvic Infection | 1 | 2018 | 4 | 0.150 |
Why?
|
Malnutrition | 1 | 2022 | 210 | 0.150 |
Why?
|
Cosmetics | 1 | 2018 | 8 | 0.150 |
Why?
|
Facial Injuries | 1 | 2019 | 22 | 0.150 |
Why?
|
Titanium | 1 | 2018 | 21 | 0.150 |
Why?
|
Metagenomics | 1 | 2019 | 103 | 0.150 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 225 | 0.150 |
Why?
|
Taste | 1 | 2018 | 33 | 0.150 |
Why?
|
Extracellular Matrix | 1 | 2020 | 241 | 0.150 |
Why?
|
Pectins | 3 | 2024 | 7 | 0.150 |
Why?
|
Phytotherapy | 1 | 2019 | 50 | 0.150 |
Why?
|
Dendrimers | 1 | 2018 | 5 | 0.150 |
Why?
|
Viral Load | 1 | 2020 | 393 | 0.150 |
Why?
|
Neurodegenerative Diseases | 1 | 2021 | 254 | 0.150 |
Why?
|
Pharmacists | 1 | 2019 | 88 | 0.150 |
Why?
|
Oligosaccharides | 1 | 2019 | 75 | 0.150 |
Why?
|
Doxycycline | 1 | 2019 | 117 | 0.150 |
Why?
|
Spinal Cord | 1 | 2020 | 307 | 0.150 |
Why?
|
Goldenhar Syndrome | 1 | 2018 | 13 | 0.150 |
Why?
|
Viscosity | 3 | 2022 | 41 | 0.150 |
Why?
|
Pain Management | 1 | 2020 | 182 | 0.150 |
Why?
|
Peritonitis | 1 | 2018 | 79 | 0.150 |
Why?
|
Polyethylene | 1 | 2018 | 18 | 0.150 |
Why?
|
Butadienes | 1 | 2018 | 20 | 0.150 |
Why?
|
Public Health Surveillance | 1 | 2018 | 40 | 0.150 |
Why?
|
Niacinamide | 1 | 2018 | 25 | 0.150 |
Why?
|
Pregnancy | 4 | 2020 | 7257 | 0.150 |
Why?
|
Kidney Function Tests | 2 | 2019 | 131 | 0.140 |
Why?
|
Polyethyleneimine | 1 | 2017 | 11 | 0.140 |
Why?
|
Palladium | 1 | 2017 | 13 | 0.140 |
Why?
|
Meglumine | 1 | 2017 | 16 | 0.140 |
Why?
|
Polychlorinated Dibenzodioxins | 1 | 2017 | 6 | 0.140 |
Why?
|
Rhizomucor | 1 | 2017 | 1 | 0.140 |
Why?
|
Stem Cells | 2 | 2020 | 715 | 0.140 |
Why?
|
Ibuprofen | 1 | 2018 | 41 | 0.140 |
Why?
|
Gout Suppressants | 1 | 2019 | 71 | 0.140 |
Why?
|
Immunity, Innate | 1 | 2020 | 375 | 0.140 |
Why?
|
Cardiac Electrophysiology | 1 | 2017 | 10 | 0.140 |
Why?
|
Spatial Analysis | 1 | 2017 | 24 | 0.140 |
Why?
|
Genes, Bacterial | 1 | 2018 | 214 | 0.140 |
Why?
|
Phenylurea Compounds | 1 | 2018 | 53 | 0.140 |
Why?
|
Aortic Valve | 2 | 2020 | 447 | 0.140 |
Why?
|
Periodicals as Topic | 1 | 2020 | 200 | 0.140 |
Why?
|
Equipment and Supplies | 1 | 2017 | 26 | 0.140 |
Why?
|
Herpes Zoster Vaccine | 1 | 2017 | 10 | 0.140 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2018 | 87 | 0.140 |
Why?
|
Recurrence | 4 | 2018 | 1400 | 0.140 |
Why?
|
Patient Outcome Assessment | 1 | 2018 | 92 | 0.140 |
Why?
|
Fundus Oculi | 1 | 2017 | 65 | 0.140 |
Why?
|
DNA | 2 | 2022 | 1621 | 0.140 |
Why?
|
Disease Models, Animal | 4 | 2021 | 4467 | 0.140 |
Why?
|
Case-Control Studies | 4 | 2019 | 3341 | 0.140 |
Why?
|
Organometallic Compounds | 1 | 2017 | 113 | 0.140 |
Why?
|
Emotions | 1 | 2020 | 349 | 0.140 |
Why?
|
Mediastinal Neoplasms | 1 | 2017 | 43 | 0.140 |
Why?
|
Trypanocidal Agents | 1 | 2017 | 30 | 0.140 |
Why?
|
Minocycline | 1 | 2017 | 37 | 0.140 |
Why?
|
Suction | 1 | 2017 | 56 | 0.140 |
Why?
|
Analysis of Variance | 2 | 2011 | 1020 | 0.140 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2017 | 29 | 0.130 |
Why?
|
Face | 1 | 2018 | 180 | 0.130 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2019 | 314 | 0.130 |
Why?
|
Opportunistic Infections | 1 | 2017 | 77 | 0.130 |
Why?
|
Steroids | 2 | 2021 | 203 | 0.130 |
Why?
|
Electronic Health Records | 3 | 2018 | 728 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 581 | 0.130 |
Why?
|
Artificial Intelligence | 1 | 2020 | 250 | 0.130 |
Why?
|
Area Under Curve | 2 | 2014 | 324 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2019 | 1282 | 0.130 |
Why?
|
Memory | 1 | 2020 | 353 | 0.130 |
Why?
|
Colitis, Ulcerative | 1 | 2019 | 212 | 0.130 |
Why?
|
Hirudins | 1 | 2016 | 38 | 0.130 |
Why?
|
Temperature | 3 | 2022 | 307 | 0.130 |
Why?
|
Salvage Therapy | 1 | 2018 | 189 | 0.130 |
Why?
|
Vibrio cholerae non-O1 | 1 | 2016 | 1 | 0.130 |
Why?
|
Actinomycetales Infections | 1 | 2016 | 13 | 0.130 |
Why?
|
Enterobacteriaceae | 1 | 2016 | 33 | 0.130 |
Why?
|
Vibrio Infections | 1 | 2016 | 16 | 0.130 |
Why?
|
Global Health | 1 | 2021 | 574 | 0.130 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 178 | 0.130 |
Why?
|
Enterobacteriaceae Infections | 1 | 2016 | 55 | 0.130 |
Why?
|
Mycobacterium tuberculosis | 1 | 2020 | 383 | 0.120 |
Why?
|
Mycoses | 1 | 2017 | 117 | 0.120 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 237 | 0.120 |
Why?
|
Surface Properties | 3 | 2022 | 85 | 0.120 |
Why?
|
Magnetic Resonance Angiography | 1 | 2016 | 165 | 0.120 |
Why?
|
Tablets | 3 | 2021 | 31 | 0.120 |
Why?
|
Lipids | 2 | 2019 | 524 | 0.120 |
Why?
|
Gout | 1 | 2019 | 164 | 0.120 |
Why?
|
Ultrasonography, Doppler | 1 | 2016 | 194 | 0.120 |
Why?
|
Intestines | 1 | 2019 | 580 | 0.120 |
Why?
|
Debridement | 2 | 2007 | 88 | 0.120 |
Why?
|
Mitral Valve Prolapse | 1 | 2015 | 26 | 0.120 |
Why?
|
Lower Extremity | 1 | 2017 | 179 | 0.120 |
Why?
|
Attitude of Health Personnel | 2 | 2019 | 678 | 0.120 |
Why?
|
Drug Compounding | 3 | 2020 | 39 | 0.120 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 140 | 0.120 |
Why?
|
Respiratory Tract Infections | 1 | 2018 | 275 | 0.120 |
Why?
|
Calorimetry, Differential Scanning | 3 | 2020 | 9 | 0.120 |
Why?
|
Peak Expiratory Flow Rate | 1 | 2015 | 18 | 0.120 |
Why?
|
Computed Tomography Angiography | 1 | 2016 | 203 | 0.120 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 1768 | 0.120 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2014 | 65 | 0.110 |
Why?
|
Acute Disease | 1 | 2017 | 1103 | 0.110 |
Why?
|
Pulmonary Valve | 1 | 2015 | 93 | 0.110 |
Why?
|
Urologic Surgical Procedures | 1 | 2014 | 57 | 0.110 |
Why?
|
Parkinson Disease | 1 | 2021 | 696 | 0.110 |
Why?
|
Echinocandins | 1 | 2014 | 44 | 0.110 |
Why?
|
Endoscopy | 1 | 2016 | 282 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2015 | 120 | 0.110 |
Why?
|
Protein Transport | 1 | 2015 | 371 | 0.110 |
Why?
|
Foreign-Body Migration | 1 | 2014 | 71 | 0.110 |
Why?
|
Child, Preschool | 4 | 2025 | 14221 | 0.110 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 309 | 0.110 |
Why?
|
Chloramphenicol | 2 | 2024 | 28 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 735 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 745 | 0.110 |
Why?
|
Spinal Cord Injuries | 1 | 2016 | 303 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 558 | 0.110 |
Why?
|
Ureteral Obstruction | 1 | 2014 | 105 | 0.110 |
Why?
|
Florida | 1 | 2013 | 79 | 0.110 |
Why?
|
Rare Diseases | 1 | 2015 | 193 | 0.110 |
Why?
|
Electrodes, Implanted | 1 | 2014 | 170 | 0.110 |
Why?
|
Causality | 1 | 2013 | 88 | 0.100 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2014 | 105 | 0.100 |
Why?
|
Urinary Tract Infections | 1 | 2016 | 236 | 0.100 |
Why?
|
Primary Health Care | 1 | 2019 | 772 | 0.100 |
Why?
|
ROC Curve | 1 | 2014 | 577 | 0.100 |
Why?
|
HEK293 Cells | 1 | 2015 | 746 | 0.100 |
Why?
|
Severity of Illness Index | 2 | 2014 | 2933 | 0.100 |
Why?
|
Reoperation | 2 | 2017 | 835 | 0.100 |
Why?
|
Furunculosis | 1 | 2012 | 4 | 0.100 |
Why?
|
Chills | 1 | 2012 | 6 | 0.100 |
Why?
|
Patient Discharge | 1 | 2016 | 497 | 0.100 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2017 | 442 | 0.100 |
Why?
|
Seizures | 1 | 2017 | 873 | 0.100 |
Why?
|
Cell Proliferation | 2 | 2021 | 2394 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 829 | 0.100 |
Why?
|
Kidney | 1 | 2019 | 1361 | 0.100 |
Why?
|
Morbidity | 3 | 2020 | 248 | 0.100 |
Why?
|
Biomimetics | 2 | 2023 | 18 | 0.100 |
Why?
|
Infant | 3 | 2022 | 12681 | 0.100 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2021 | 949 | 0.090 |
Why?
|
Acrylamides | 2 | 2023 | 20 | 0.090 |
Why?
|
Acyclovir | 1 | 2011 | 46 | 0.090 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 343 | 0.090 |
Why?
|
Spinal Diseases | 1 | 2011 | 45 | 0.090 |
Why?
|
Heart Diseases | 1 | 2016 | 503 | 0.090 |
Why?
|
Valine | 1 | 2011 | 111 | 0.090 |
Why?
|
Exanthema | 1 | 2012 | 71 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2013 | 321 | 0.090 |
Why?
|
Models, Molecular | 3 | 2020 | 1081 | 0.090 |
Why?
|
Blood-Borne Pathogens | 1 | 2011 | 4 | 0.090 |
Why?
|
Renal Insufficiency | 1 | 2014 | 242 | 0.090 |
Why?
|
Metronidazole | 1 | 2011 | 154 | 0.090 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2015 | 306 | 0.090 |
Why?
|
Intensive Care Units | 1 | 2014 | 501 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2011 | 163 | 0.090 |
Why?
|
Gram-Positive Cocci | 1 | 2010 | 2 | 0.090 |
Why?
|
Aspirin | 1 | 2012 | 223 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 355 | 0.090 |
Why?
|
Proportional Hazards Models | 2 | 2012 | 1380 | 0.090 |
Why?
|
Health Planning Guidelines | 1 | 2010 | 33 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 1685 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2019 | 1077 | 0.080 |
Why?
|
Porosity | 2 | 2020 | 40 | 0.080 |
Why?
|
Oxygen | 2 | 2022 | 557 | 0.080 |
Why?
|
Powder Diffraction | 2 | 2021 | 2 | 0.080 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2013 | 346 | 0.080 |
Why?
|
Drug Stability | 2 | 2020 | 60 | 0.080 |
Why?
|
Diabetes Mellitus, Experimental | 2 | 2021 | 139 | 0.080 |
Why?
|
Tissue Engineering | 2 | 2023 | 175 | 0.080 |
Why?
|
Age of Onset | 1 | 2011 | 608 | 0.080 |
Why?
|
Myocarditis | 1 | 2010 | 132 | 0.080 |
Why?
|
Case Management | 1 | 2009 | 21 | 0.080 |
Why?
|
Smoking | 1 | 2015 | 1050 | 0.080 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2013 | 515 | 0.080 |
Why?
|
Microscopy, Electron, Scanning | 2 | 2020 | 148 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2011 | 311 | 0.080 |
Why?
|
DNA, Bacterial | 2 | 2021 | 475 | 0.080 |
Why?
|
Biomarkers | 1 | 2018 | 3153 | 0.080 |
Why?
|
Stents | 1 | 2014 | 839 | 0.070 |
Why?
|
Phenotype | 1 | 2018 | 4323 | 0.070 |
Why?
|
Mannose-Binding Lectins | 2 | 2019 | 26 | 0.070 |
Why?
|
Molecular Docking Simulation | 2 | 2021 | 113 | 0.070 |
Why?
|
Ecthyma, Contagious | 1 | 2008 | 1 | 0.070 |
Why?
|
Erythrocytes | 2 | 2020 | 223 | 0.070 |
Why?
|
Poxviridae | 1 | 2008 | 4 | 0.070 |
Why?
|
Sheep Diseases | 1 | 2008 | 7 | 0.070 |
Why?
|
Skin Diseases, Infectious | 1 | 2008 | 24 | 0.070 |
Why?
|
Lectins, C-Type | 2 | 2019 | 73 | 0.070 |
Why?
|
Patient Readmission | 1 | 2011 | 393 | 0.070 |
Why?
|
Zoonoses | 1 | 2008 | 44 | 0.070 |
Why?
|
Anticoagulants | 2 | 2022 | 579 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2015 | 1551 | 0.070 |
Why?
|
Surveys and Questionnaires | 1 | 2017 | 3716 | 0.070 |
Why?
|
Survival Analysis | 3 | 2017 | 1517 | 0.070 |
Why?
|
Fungi | 2 | 2021 | 70 | 0.070 |
Why?
|
Inhibitory Concentration 50 | 2 | 2018 | 80 | 0.070 |
Why?
|
In Vitro Techniques | 2 | 2021 | 973 | 0.070 |
Why?
|
Rats, Sprague-Dawley | 2 | 2020 | 1261 | 0.070 |
Why?
|
Antioxidants | 2 | 2020 | 356 | 0.070 |
Why?
|
Colon | 2 | 2020 | 358 | 0.070 |
Why?
|
Factor Analysis, Statistical | 1 | 2007 | 218 | 0.070 |
Why?
|
Probability | 1 | 2007 | 321 | 0.070 |
Why?
|
Computer Simulation | 2 | 2020 | 664 | 0.060 |
Why?
|
Receptors, Cell Surface | 2 | 2019 | 480 | 0.060 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2006 | 86 | 0.060 |
Why?
|
Urogenital System | 1 | 2005 | 34 | 0.060 |
Why?
|
Escherichia coli | 2 | 2020 | 974 | 0.060 |
Why?
|
Lung Diseases, Fungal | 1 | 2005 | 32 | 0.060 |
Why?
|
Motion Sickness | 1 | 2005 | 10 | 0.060 |
Why?
|
Corynebacterium Infections | 1 | 2005 | 4 | 0.060 |
Why?
|
Respiration, Artificial | 2 | 2021 | 477 | 0.060 |
Why?
|
Genotype | 2 | 2021 | 2594 | 0.060 |
Why?
|
Patient Safety | 2 | 2020 | 400 | 0.060 |
Why?
|
Biodegradation, Environmental | 1 | 2024 | 13 | 0.060 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2005 | 37 | 0.060 |
Why?
|
Sudden Infant Death | 1 | 2005 | 36 | 0.060 |
Why?
|
Chenopodiaceae | 1 | 2024 | 1 | 0.060 |
Why?
|
Salt-Tolerant Plants | 1 | 2024 | 1 | 0.060 |
Why?
|
Lung Neoplasms | 1 | 2014 | 1668 | 0.060 |
Why?
|
RNA, Viral | 2 | 2022 | 538 | 0.060 |
Why?
|
Laccase | 1 | 2024 | 4 | 0.060 |
Why?
|
Body Surface Area | 1 | 2024 | 31 | 0.060 |
Why?
|
Organs at Risk | 1 | 2024 | 25 | 0.060 |
Why?
|
Shoulder Injuries | 1 | 2004 | 6 | 0.060 |
Why?
|
Nanofibers | 1 | 2024 | 19 | 0.060 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 64 | 0.060 |
Why?
|
Registries | 3 | 2018 | 1454 | 0.060 |
Why?
|
Radiation Dosage | 1 | 2024 | 137 | 0.050 |
Why?
|
Paralysis | 1 | 2003 | 34 | 0.050 |
Why?
|
Spectrometry, Gamma | 1 | 2023 | 1 | 0.050 |
Why?
|
Thorium | 1 | 2023 | 1 | 0.050 |
Why?
|
Potassium Radioisotopes | 1 | 2023 | 7 | 0.050 |
Why?
|
Cefotaxime | 1 | 2023 | 36 | 0.050 |
Why?
|
Cesium Radioisotopes | 1 | 2023 | 5 | 0.050 |
Why?
|
Biomass | 1 | 2023 | 18 | 0.050 |
Why?
|
Databases, Factual | 2 | 2020 | 1193 | 0.050 |
Why?
|
Cefoxitin | 1 | 2023 | 5 | 0.050 |
Why?
|
Methylcellulose | 1 | 2023 | 6 | 0.050 |
Why?
|
Linezolid | 1 | 2023 | 25 | 0.050 |
Why?
|
Erythromycin | 1 | 2023 | 20 | 0.050 |
Why?
|
Clindamycin | 1 | 2023 | 41 | 0.050 |
Why?
|
Suspensions | 1 | 2022 | 9 | 0.050 |
Why?
|
Skin Absorption | 1 | 2022 | 7 | 0.050 |
Why?
|
Aflatoxin B1 | 1 | 2022 | 2 | 0.050 |
Why?
|
Micelles | 1 | 2022 | 17 | 0.050 |
Why?
|
Electromyography | 1 | 2003 | 163 | 0.050 |
Why?
|
Salinity | 1 | 2022 | 3 | 0.050 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2022 | 13 | 0.050 |
Why?
|
Electrophysiology | 1 | 2003 | 275 | 0.050 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2022 | 51 | 0.050 |
Why?
|
Risk | 1 | 2005 | 769 | 0.050 |
Why?
|
Emulsions | 1 | 2022 | 70 | 0.050 |
Why?
|
Dehydration | 1 | 2022 | 40 | 0.050 |
Why?
|
Hypersensitivity | 1 | 2005 | 188 | 0.050 |
Why?
|
Enzyme Stability | 1 | 2022 | 58 | 0.050 |
Why?
|
Galactans | 1 | 2022 | 3 | 0.050 |
Why?
|
Plant Gums | 1 | 2022 | 3 | 0.050 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2005 | 102 | 0.050 |
Why?
|
Administration, Topical | 1 | 2022 | 139 | 0.050 |
Why?
|
Chondroitin Sulfates | 1 | 2022 | 14 | 0.050 |
Why?
|
DNA, Single-Stranded | 1 | 2022 | 74 | 0.050 |
Why?
|
Magnetic Phenomena | 1 | 2022 | 5 | 0.050 |
Why?
|
Sodium Chloride | 1 | 2022 | 96 | 0.050 |
Why?
|
Mannans | 1 | 2022 | 13 | 0.050 |
Why?
|
Oligonucleotides | 1 | 2022 | 91 | 0.050 |
Why?
|
Exodeoxyribonucleases | 1 | 2022 | 51 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 1129 | 0.050 |
Why?
|
Keratins | 1 | 2022 | 52 | 0.050 |
Why?
|
Agricultural Irrigation | 1 | 2022 | 2 | 0.050 |
Why?
|
Serum Albumin | 1 | 2022 | 114 | 0.050 |
Why?
|
Food Chain | 1 | 2022 | 11 | 0.050 |
Why?
|
Crops, Agricultural | 1 | 2022 | 16 | 0.050 |
Why?
|
Biomimetic Materials | 1 | 2021 | 12 | 0.050 |
Why?
|
Floods | 1 | 2022 | 14 | 0.050 |
Why?
|
Genes, rRNA | 1 | 2021 | 19 | 0.050 |
Why?
|
Vegetables | 1 | 2024 | 264 | 0.050 |
Why?
|
Colistin | 1 | 2022 | 31 | 0.050 |
Why?
|
Animal Feed | 1 | 2022 | 78 | 0.050 |
Why?
|
Rheology | 1 | 2021 | 34 | 0.050 |
Why?
|
Age Factors | 2 | 2021 | 2835 | 0.050 |
Why?
|
Streptozocin | 1 | 2021 | 25 | 0.050 |
Why?
|
3T3-L1 Cells | 1 | 2021 | 51 | 0.050 |
Why?
|
Transportation | 1 | 2021 | 27 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2013 | 588 | 0.050 |
Why?
|
Thinness | 1 | 2022 | 72 | 0.050 |
Why?
|
Elasticity | 1 | 2021 | 94 | 0.050 |
Why?
|
Bone and Bones | 1 | 2023 | 271 | 0.050 |
Why?
|
Palate, Soft | 1 | 2021 | 16 | 0.050 |
Why?
|
Bread | 1 | 2021 | 5 | 0.050 |
Why?
|
Infectious Disease Incubation Period | 1 | 2021 | 7 | 0.050 |
Why?
|
Air Microbiology | 1 | 2021 | 11 | 0.050 |
Why?
|
Polymyxin B | 1 | 2022 | 47 | 0.040 |
Why?
|
Chemistry Techniques, Analytical | 1 | 2020 | 8 | 0.040 |
Why?
|
Speech Disorders | 1 | 2021 | 44 | 0.040 |
Why?
|
Drug Synergism | 1 | 2021 | 228 | 0.040 |
Why?
|
Pyrimidines | 1 | 2004 | 389 | 0.040 |
Why?
|
Chronic Disease | 1 | 2025 | 1204 | 0.040 |
Why?
|
Silicon Dioxide | 1 | 2020 | 26 | 0.040 |
Why?
|
Speech | 1 | 2021 | 62 | 0.040 |
Why?
|
Stress, Physiological | 1 | 2022 | 262 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2021 | 121 | 0.040 |
Why?
|
Symptom Assessment | 1 | 2021 | 101 | 0.040 |
Why?
|
Mastectomy | 1 | 2020 | 67 | 0.040 |
Why?
|
MCF-7 Cells | 1 | 2021 | 224 | 0.040 |
Why?
|
Ammonium Sulfate | 1 | 2020 | 12 | 0.040 |
Why?
|
Thermogravimetry | 1 | 2020 | 6 | 0.040 |
Why?
|
Polymerization | 1 | 2020 | 14 | 0.040 |
Why?
|
alpha-Synuclein | 1 | 2021 | 125 | 0.040 |
Why?
|
Acute Lung Injury | 1 | 2021 | 65 | 0.040 |
Why?
|
Penicillins | 1 | 2020 | 154 | 0.040 |
Why?
|
Thrombosis | 1 | 2005 | 524 | 0.040 |
Why?
|
Global Burden of Disease | 1 | 2020 | 27 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 383 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2020 | 67 | 0.040 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2020 | 129 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2021 | 176 | 0.040 |
Why?
|
Genes, Mitochondrial | 1 | 2019 | 17 | 0.040 |
Why?
|
Sulfasalazine | 1 | 2019 | 3 | 0.040 |
Why?
|
Primary Prevention | 1 | 2021 | 172 | 0.040 |
Why?
|
Gels | 1 | 2019 | 70 | 0.040 |
Why?
|
Muramidase | 1 | 2019 | 95 | 0.040 |
Why?
|
Administration, Intranasal | 1 | 2019 | 133 | 0.040 |
Why?
|
Chitin | 1 | 2019 | 5 | 0.040 |
Why?
|
Gene Editing | 1 | 2021 | 187 | 0.040 |
Why?
|
Hypoxia | 1 | 2021 | 256 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 219 | 0.040 |
Why?
|
Chemical Phenomena | 1 | 2019 | 87 | 0.040 |
Why?
|
Chemical Fractionation | 1 | 2019 | 14 | 0.040 |
Why?
|
Dynamic Light Scattering | 1 | 2019 | 9 | 0.040 |
Why?
|
Australia | 1 | 2019 | 146 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2019 | 48 | 0.040 |
Why?
|
Adsorption | 1 | 2018 | 34 | 0.040 |
Why?
|
Professional Role | 1 | 2019 | 61 | 0.040 |
Why?
|
Leishmania donovani | 1 | 2019 | 24 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2019 | 103 | 0.040 |
Why?
|
Spectrum Analysis | 1 | 2019 | 66 | 0.040 |
Why?
|
Abdomen, Acute | 1 | 2018 | 14 | 0.040 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 323 | 0.040 |
Why?
|
Species Specificity | 1 | 2019 | 552 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2019 | 37 | 0.040 |
Why?
|
Molecular Conformation | 1 | 2018 | 107 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2019 | 72 | 0.040 |
Why?
|
Workflow | 1 | 2019 | 119 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2022 | 867 | 0.040 |
Why?
|
Canada | 1 | 2019 | 291 | 0.040 |
Why?
|
Powders | 1 | 2018 | 24 | 0.040 |
Why?
|
Healthy Volunteers | 1 | 2018 | 137 | 0.040 |
Why?
|
Adhesiveness | 1 | 2018 | 14 | 0.040 |
Why?
|
Europe | 1 | 2019 | 362 | 0.040 |
Why?
|
Uric Acid | 1 | 2019 | 102 | 0.040 |
Why?
|
Injury Severity Score | 1 | 2019 | 219 | 0.040 |
Why?
|
Molecular Structure | 1 | 2019 | 295 | 0.040 |
Why?
|
Nitrophenols | 1 | 2017 | 16 | 0.040 |
Why?
|
Hep G2 Cells | 1 | 2018 | 89 | 0.040 |
Why?
|
Glucose | 1 | 2022 | 881 | 0.040 |
Why?
|
Citrates | 1 | 2017 | 24 | 0.040 |
Why?
|
Interprofessional Relations | 1 | 2019 | 151 | 0.040 |
Why?
|
Hemolysis | 1 | 2018 | 112 | 0.040 |
Why?
|
Atrophy | 1 | 2018 | 234 | 0.040 |
Why?
|
Receptors, Scavenger | 1 | 2017 | 3 | 0.040 |
Why?
|
Catalysis | 1 | 2017 | 129 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2011 | 3622 | 0.040 |
Why?
|
Permeability | 1 | 2018 | 125 | 0.040 |
Why?
|
Cardiology Service, Hospital | 1 | 2017 | 15 | 0.040 |
Why?
|
Immunomodulation | 1 | 2018 | 80 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 580 | 0.030 |
Why?
|
Plants | 1 | 2017 | 47 | 0.030 |
Why?
|
Gold | 1 | 2017 | 48 | 0.030 |
Why?
|
United Kingdom | 1 | 2018 | 202 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2021 | 508 | 0.030 |
Why?
|
Phylogeny | 1 | 2019 | 690 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2018 | 393 | 0.030 |
Why?
|
Cholesterol, HDL | 1 | 2019 | 356 | 0.030 |
Why?
|
Sex Factors | 1 | 2021 | 1293 | 0.030 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2018 | 76 | 0.030 |
Why?
|
Biological Transport | 1 | 2017 | 353 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 91 | 0.030 |
Why?
|
Treatment Failure | 1 | 2018 | 337 | 0.030 |
Why?
|
Drainage | 1 | 2018 | 260 | 0.030 |
Why?
|
Electrophysiological Phenomena | 1 | 2017 | 67 | 0.030 |
Why?
|
Propensity Score | 1 | 2017 | 228 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2019 | 803 | 0.030 |
Why?
|
Hematoma | 1 | 2017 | 92 | 0.030 |
Why?
|
Cornea | 1 | 2021 | 661 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2017 | 447 | 0.030 |
Why?
|
Mortality | 1 | 2018 | 243 | 0.030 |
Why?
|
Triglycerides | 1 | 2019 | 577 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2019 | 443 | 0.030 |
Why?
|
Serotyping | 1 | 2016 | 178 | 0.030 |
Why?
|
Streptococcus | 1 | 2016 | 59 | 0.030 |
Why?
|
Cell Membrane | 1 | 2018 | 467 | 0.030 |
Why?
|
Environment | 1 | 2016 | 144 | 0.030 |
Why?
|
Bacterial Typing Techniques | 1 | 2016 | 99 | 0.030 |
Why?
|
Patient Preference | 1 | 2016 | 122 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2018 | 517 | 0.030 |
Why?
|
Cholesterol, LDL | 1 | 2019 | 568 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 1111 | 0.030 |
Why?
|
Blood Glucose | 1 | 2019 | 1142 | 0.030 |
Why?
|
Ureteroscopy | 1 | 2014 | 17 | 0.030 |
Why?
|
Wounds and Injuries | 1 | 2018 | 375 | 0.030 |
Why?
|
Resuscitation Orders | 1 | 2014 | 32 | 0.030 |
Why?
|
Nitric Oxide | 1 | 2018 | 485 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 1251 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 257 | 0.030 |
Why?
|
Decision Support Systems, Clinical | 1 | 2016 | 170 | 0.030 |
Why?
|
Substance Abuse, Intravenous | 1 | 2014 | 38 | 0.030 |
Why?
|
Peripartum Period | 1 | 2014 | 29 | 0.030 |
Why?
|
Rheumatic Heart Disease | 1 | 2014 | 38 | 0.030 |
Why?
|
Maternal Mortality | 1 | 2014 | 80 | 0.030 |
Why?
|
Blood Pressure | 1 | 2019 | 1357 | 0.030 |
Why?
|
Palivizumab | 1 | 2013 | 47 | 0.030 |
Why?
|
Ureter | 1 | 2014 | 95 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2014 | 239 | 0.030 |
Why?
|
Organ Transplantation | 1 | 2015 | 170 | 0.030 |
Why?
|
History, 21st Century | 1 | 2014 | 271 | 0.030 |
Why?
|
Infant Mortality | 1 | 2014 | 176 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2019 | 3040 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2014 | 1064 | 0.030 |
Why?
|
Sweating | 1 | 2012 | 7 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 2013 | 167 | 0.020 |
Why?
|
Physicians | 1 | 2019 | 603 | 0.020 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2013 | 148 | 0.020 |
Why?
|
Cell Line | 1 | 2017 | 2734 | 0.020 |
Why?
|
Blotting, Western | 1 | 2014 | 1110 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2015 | 281 | 0.020 |
Why?
|
Radiography | 1 | 2014 | 805 | 0.020 |
Why?
|
Drug Resistance, Microbial | 1 | 2012 | 192 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2012 | 369 | 0.020 |
Why?
|
Leukocytes | 1 | 2012 | 213 | 0.020 |
Why?
|
Phosphorylation | 1 | 2014 | 1640 | 0.020 |
Why?
|
Drug Implants | 1 | 2010 | 42 | 0.020 |
Why?
|
New York | 1 | 2010 | 68 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 554 | 0.020 |
Why?
|
Brain | 1 | 2022 | 3034 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2012 | 266 | 0.020 |
Why?
|
Critical Illness | 1 | 2014 | 603 | 0.020 |
Why?
|
United Arab Emirates | 1 | 2008 | 1 | 0.020 |
Why?
|
Quality of Life | 1 | 2018 | 1954 | 0.020 |
Why?
|
Apoptosis | 1 | 2014 | 1839 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 2194 | 0.020 |
Why?
|
Keratinocytes | 1 | 2008 | 63 | 0.020 |
Why?
|
Lung | 1 | 2014 | 1508 | 0.020 |
Why?
|
DNA, Viral | 1 | 2008 | 479 | 0.020 |
Why?
|
Monocytes | 1 | 2008 | 347 | 0.020 |
Why?
|
Electrocardiography | 1 | 2010 | 981 | 0.010 |
Why?
|
Base Sequence | 1 | 2008 | 3118 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2008 | 3901 | 0.010 |
Why?
|
Heart Defects, Congenital | 1 | 2014 | 1838 | 0.010 |
Why?
|
Signal Transduction | 1 | 2014 | 4638 | 0.010 |
Why?
|